Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.

Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I; Japanese Childhood AML Cooperative Study Group.

J Clin Oncol. 2007 Dec 1;25(34):5442-7.

PMID:
18048827
2.

Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group.

Pediatr Blood Cancer. 2007 Aug;49(2):127-32.

PMID:
16807916
3.

An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.

Kojima S, Sako M, Kato K, Hosoi G, Sato T, Ohara A, Koike K, Okimoto Y, Nishimura S, Akiyama Y, Yoshikawa T, Ishii E, Okamura J, Yazaki M, Hayashi Y, Eguchi M, Tsukimoto I, Ueda K.

Leukemia. 2000 May;14(5):786-91.

PMID:
10803507
4.

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO; Children's Cancer Group Study 2891.

J Clin Oncol. 2003 Sep 15;21(18):3415-22. Epub 2003 Jul 28.

PMID:
12885836
5.

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA; Children's Cancer Group Study 2951.

J Clin Oncol. 2003 Aug 1;21(15):2940-7.

PMID:
12885813
7.

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.

J Clin Oncol. 2006 Sep 20;24(27):4499-506.

PMID:
16983120
8.

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.

Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Shimada A, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, Adachi S.

Pediatr Blood Cancer. 2016 Feb;63(2):248-54. doi: 10.1002/pbc.25789. Epub 2015 Oct 20.

PMID:
26481183
9.

Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.

Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, et al.

Blood. 1992 Nov 1;80(9):2210-4.

10.

Maintenance therapy in childhood acute myeloid leukemia.

Perel Y, Auvrignon A, Leblanc T, Michel G, Vannier JP, Dalle JH, Gandemer V, Schmitt C, Mèchinaud F, Lamagnere JP, Piguet Ch, Couillaud G, Pautard B, Baruchel A, Leverger G; Group LAME; French Society of Pediatric Hematology and Immunology.

Ann Hematol. 2004;83 Suppl 1:S116-9.

PMID:
15124700
11.

Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.

Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.

Am J Hematol. 2004 Aug;76(4):319-29.

12.

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R.

J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20.

PMID:
19620491
13.

Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.

Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y, Oda T, Oda M, Nishimura S, Imaizumi M, Okamura T, Hongo T, Okawa H, Mizutani S, Hayashi Y, Tsukimoto I, Kamada N, Ishii E.

Blood. 2001 Dec 15;98(13):3589-94.

14.

Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.

Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG.

Blood. 1998 Jan 15;91(2):608-15.

15.

Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.

Taga T, Shimomura Y, Horikoshi Y, Ogawa A, Itoh M, Okada M, Ueyama J, Higa T, Watanabe A, Kanegane H, Iwai A, Saiwakawa Y, Kogawa K, Yamanaka J, Tsurusawa M.

Pediatr Blood Cancer. 2011 Jul 15;57(1):36-40. doi: 10.1002/pbc.22943. Epub 2010 Dec 30.

PMID:
21557456
16.

No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R, et al.

Int J Hematol. 1999 Aug;70(2):97-104.

PMID:
10497848
17.
18.

Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.

Zubizarreta P, Felice MS, Alfaro E, Fraquelli L, Casak S, Quinteros R, Cygler A, Gallego M, Pérez LE, Sackmann-Muriel F.

Leuk Res. 1998 May;22(5):465-72.

PMID:
9652734
19.

Long-term outcomes of de novo acute myeloid leukemia in Thai patients.

Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.

J Med Assoc Thai. 2009 Sep;92(9):1143-9.

PMID:
19772172
20.

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD.

J Clin Oncol. 2005 Jan 20;23(3):482-93. Epub 2004 Nov 8.

PMID:
15534356

Supplemental Content

Support Center